Unmet Needs and Treatment Options in Gastrointestinal Stromal Tumor

Insights from 2024 ASCO® GI Annual Meeting
J

INSIGHT: A Phase 3 Study of Ripretinib vs. Sunitinib in Pts With Advanced GIST Previously Treated With Imatinib With KIT Exon 11 + 17/18 Mutations

By Insights from 2024 ASCO® GI Annual Meeting FEATURING John Zalcberg
By Insights from 2024 ASCO® GI Annual Meeting FEATURING John Zalcberg
186 views
March 20, 2024
0 Comments
Login to view comments. Click here to Login
25:23

NCCN Clinical Practice Guidelines for Treating GIST

Andrea Napolitano

394 views
07:00

ctDNA Analysis From INTRIGUE Study: Updated OS & Safety With Ripreti…

Insights from 2024 ESMO Sarcoma and Rare Cancers Congress

J. Blay

192 views
19:40

Gastrointestinal Stromal Tumors (GIST) and Resistance Mutations

Warren Chow

348 views
28:09

What Is the “Normal” Sarcoma Immune Microenvironment?

MedNews Week

S. Pollack

221 views
11:03

Final Analyses From INTRIGUE: OS & Long-Term Safety With Ripretinib …

Insights from 2024 ASCO® GI Annual Meeting

J. Zalcberg

178 views
22:07

2024 Update in Sarcomas

Total Health

D. Portnoy

530 views